SCHEMBL30630102

SCHEMBL30630102

N#Cc1c2c(c(Cl)n3c1nc1ccccc13)CCCC2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.62
KMT2A Q03164 5/20 0.61
NPSR1 Q6W5P4 5/20 0.61
MEN1 O00255 4/20 0.61
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2C9 P11712 1/20 0.61
ATM Q13315 1/20 0.61
RXFP1 Q9HBX9 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
MAPT P10636 6/20 0.58
CASP1 P29466 6/20 0.58
ALDH1A1 P00352 5/20 0.58
TSHR P16473 5/20 0.58
CASP7 P55210 5/20 0.58
GLA P06280 3/20 0.58
SMN1; SMN2 Q16637 4/20 0.57
HTT P42858 3/20 0.57
GAA P10253 2/20 0.57
PKM P14618 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14716159 0.97 KDM4E (0.65) KDM4EKMT2ANPSR1MEN1CYP1A2
SCHEMBL14716146 0.84 KDM4E (0.51) KDM4EKMT2ANPSR1MEN1CYP1A2
SCHEMBL14728254 0.82 MAPT (0.52) KDM4EKMT2ANPSR1MEN1CYP1A2
SCHEMBL14728253 0.81 MAPT (0.56) KDM4EKMT2ANPSR1MEN1CYP1A2
SCHEMBL26702811 0.81 KDM4E (0.80) KDM4EKMT2ANPSR1MEN1CYP1A2
SCHEMBL26703074 0.80 KDM4E (0.75) KDM4EKMT2ANPSR1MEN1CYP1A2
SCHEMBL26608114 0.79 KDM4E (0.95) KDM4EKMT2ANPSR1MEN1CYP1A2
SCHEMBL26703076 0.79 KDM4E (0.74) KDM4EKMT2ANPSR1MEN1CYP1A2
SCHEMBL14728219 0.78 MAPK1 (0.77) KDM4EKMT2ANPSR1MEN1CYP1A2
SCHEMBL26702990 0.77 KDM4E (0.82) KDM4EKMT2ANPSR1MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624031-B2 Inhibitors of ubiquitin specific peptidase 22 (USP22) and uses thereof for treating diseases and disorders NORTHWESTERN UNIVERSITY (US) 2026-05-12 US disclosed
US-20230339942-A1 INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASES AND DISORDERS NORTHWESTERN UNIVERSITY 2023-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12624031-B2 Inhibitors of ubiquitin specific peptidase 22 (USP22) and uses thereof for treating diseases and disorders USP2, USP19, USP24 KDM4E 451/4885KMT2A 453/4885NPSR1 4407/4885
US-20230339942-A1 INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASES AND DISORDERS USP19, USP24, USP2 KDM4E 1113/4885KMT2A 1263/4885NPSR1 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.